Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Atara Biotherapeutics, Inc. (ATRA)
USD8.47
+0.43 (+5.35%)
US NASDAQ Healthcare Biotechnology
Address
611 Gateway Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Anhco Nguyen
Website
atarabio.com
IPO
2014-10-16
CIK 1604464 ISIN US0465132068
Also trades on
London Stock Exchange · 0HIY.L (USD)
NASDAQ Global Select · ATRA (USD)
Description
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.47
+0.43 (+5.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.09
Float Shares
5.95M
Free Float %
66.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.66% | +9.02% | +120.34% | +93.91% | -30.40% | -41.90% | +34.74% | -74.05% | -96.99% | -97.68% | -96.05% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Hold
Price Targets & DCF
Current price
8.47
Low
6.00
-29.2%
Consensus
9.50
+12.2%
Median
9.50
+12.2%
High
13.00
+53.5%
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | +1 |
| Hold | 1 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
13.00
+53.5%
|
| Last Quarter | 1 |
13.00
+53.5%
|
| Last Year | 3 |
14.67
+73.2%
|
| All Time | 7 |
11.29
+33.3%
|
Quality scores
Altman Z-Score
-140.27
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-6.3% Q1'26: -99.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+122.5% ★ Q1'26: -108.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-57.9% Q1'26: -595.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+30.2% ★ Q1'26: -652.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+627.4% ★ Q1'26: +36.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+69.9% Q1'26: +29.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.37× Q1'26: -0.68× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 15.00M (-100.0%)
|
20.34M
est: 41.63M (-51.1%)
|
63.57M
est: 96.77M (-34.3%)
|
8.57M
est: 34.70M (-75.3%)
|
128.94M
est: 116.64M (+10.5%)
|
120.77M
est: 121.72M (-0.8%)
|
7.77M
6.75M – 9.30M
-93.6% YoY
|
48.52M
42.17M – 58.09M
+524.3% YoY
|
27.75M
24.12M – 33.23M
-42.8% YoY
|
55.67M
48.38M – 66.65M
+100.6% YoY
|
80.79M
70.21M – 96.72M
+45.1% YoY
|
| EBITDA |
-300.72M
est: -7.76M (-3,774.0%)
|
-331.12M
est: -299.18M (-10.7%)
|
-222.26M
est: -322.34M (+31.0%)
|
-266.00M
est: -22.00M (-1,108.9%)
|
-75.75M
est: -76.22M (+0.6%)
|
38.63M
est: -79.55M (+148.6%)
|
-5.08M
-6.08M – -4.41M
+93.6% YoY
|
-31.71M
-37.97M – -27.56M
-524.3% YoY
|
-18.14M
-21.72M – -15.76M
+42.8% YoY
|
-36.38M
-43.56M – -31.62M
-100.6% YoY
|
-52.80M
-63.21M – -45.88M
-45.1% YoY
|
| EBIT |
-309.05M
est: -7.88M (-3,822.0%)
|
-340.46M
est: -308.00M (-10.5%)
|
-227.92M
est: -333.72M (+31.7%)
|
-270.83M
est: -22.31M (-1,113.8%)
|
-80.80M
est: -77.55M (-4.2%)
|
36.51M
est: -80.93M (+145.1%)
|
-5.17M
-6.19M – -4.49M
+93.6% YoY
|
-32.26M
-38.62M – -28.04M
-524.3% YoY
|
-18.45M
-22.09M – -16.04M
+42.8% YoY
|
-37.01M
-44.32M – -32.17M
-100.6% YoY
|
-53.71M
-64.31M – -46.68M
-45.1% YoY
|
| Net Income |
-306.62M
est: -727.77M (+57.9%)
|
-340.14M
est: -307.71M (-10.5%)
|
-228.30M
est: -233.47M (+2.2%)
|
-276.13M
est: -644.12M (+57.1%)
|
-85.40M
est: -88.50M (+3.5%)
|
32.69M
est: 38.03M (-14.0%)
|
-10.56M
-12.71M – -8.40M
-127.8% YoY
|
8.82M
7.02M – 10.63M
+183.6% YoY
|
-4.34M
-11.57M – 2.89M
-149.2% YoY
|
25.31M
21.00M – 31.80M
+683.4% YoY
|
39.50M
32.77M – 49.63M
+56.1% YoY
|
| SGA |
64.40M
est: 36.74M (+75.3%)
|
78.80M
est: 101.96M (-22.7%)
|
71.55M
est: 237.02M (-69.8%)
|
50.91M
est: 79.57M (-36.0%)
|
39.89M
est: 267.44M (-85.1%)
|
26.25M
est: 279.09M (-90.6%)
|
17.82M
15.49M – 21.34M
-93.6% YoY
|
111.26M
96.69M – 133.20M
+524.3% YoY
|
63.64M
55.30M – 76.19M
-42.8% YoY
|
127.65M
110.93M – 152.83M
+100.6% YoY
|
185.24M
160.97M – 221.77M
+45.1% YoY
|
| EPS |
-103.63
est: -97.19 (-6.6%)
|
-90.78
est: -83.35 (-8.9%)
|
-55.96
est: -50.03 (-11.8%)
|
-65.18
est: -50.65 (-28.7%)
|
-11.41
est: -7.33 (-55.6%)
|
2.61
est: 2.87 (-9.0%)
|
-0.80
-1.00 – -0.66
-127.8% YoY
|
0.66
0.55 – 0.84
+183.6% YoY
|
-0.30
-0.91 – 0.23
-145.1% YoY
|
1.99
1.65 – 2.50
+763.3% YoY
|
3.11
2.58 – 3.90
+56.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-18 | Freedom Broker | Sell | Hold | Upgrade |
| 2026-05-08 | Canaccord Genuity | Hold | Buy | Upgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-228.96M
OE per share TTM
-16.93
Owner's Yield
-154.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
115.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
34
Total invested
12.13M
Insider transactions (90d)
4
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 10.07M | 11.00% | — | — | — | 10.07M | IA, OO | Delaware | 2023-11-21 | ↗ |
| 2 | Oleg Nodelman | 10.07M | 11.00% | — | — | — | 10.07M | HC, IN | Delaware | 2023-11-21 | ↗ |
| 3 | EcoR1 Capital Fund Qualified, L.P. | 9.50M | 11.00% | — | — | — | 9.50M | PN | Delaware | 2023-11-21 | ↗ |
| 4 | Jeremy C. Green | 9.10M | 9.90% | — | 9.10M | — | — | HC, IN | United Kingdom | 2022-02-14 | ↗ |
| 5 | Redmile Group, LLC | 9.10M | 9.90% | — | 9.10M | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
| 6 | Wasatch Advisors LP 87-0319391 | 8.39M | 8.80% | 8.39M | — | — | — | IA | — | 2023-02-08 | ↗ |
| 7 | Baupost Group GP, L.L.C.82-3254604 | 8.12M | 9.19% | — | 8.12M | — | 8.12M | HC | Delaware | 2022-02-09 | ↗ |
| 8 | Seth A. Klarman | 8.12M | 9.19% | — | 8.12M | — | 8.12M | HC | Delaware | 2022-02-09 | ↗ |
| 9 | The Baupost Group, L.L.C.04-3402144 | 8.12M | 9.19% | — | 8.12M | — | 8.12M | IA | Delaware | 2022-02-09 | ↗ |
| 10 | Adiumentum Capital Fund I GP LLC | 8.07M | 6.70% | — | 8.07M | — | 10.00 | IA | Delaware | 2024-05-22 | ↗ |
| 11 | Adiumentum Capital Fund I LP | 8.07M | 6.70% | — | 8.07M | — | 10.00 | IA | Delaware | 2024-05-22 | ↗ |
| 12 | Gregory A. Ciongoli | 8.07M | 6.70% | — | 8.07M | — | 10.00 | IN | United States | 2024-05-22 | ↗ |
| 13 | Ltd. – 75-2482446 | 7.86M | 8.90% | — | 7.86M | — | 7.86M | IA | — | 2022-02-15 | ↗ |
| 14 | Management, LLC – 75-2686461 | 7.86M | 8.90% | — | 7.86M | — | 7.86M | HC | — | 2022-02-15 | ↗ |
| 15 | 75-2482446 | 7.86M | 8.40% | — | 7.86M | — | 7.86M | IA | Texas | 2022-03-11 | ↗ |
| 16 | III | 7.86M | 8.40% | — | 7.86M | — | 7.86M | IN | Texas | 2022-03-11 | ↗ |
| 17 | (1) BlackRock, Inc. | 7.82M | 8.80% | 7.48M | — | 7.82M | — | HC | Delaware | 2022-02-03 | ↗ |
| 18 | STATE STREET CORPORATION | 7.65M | 8.06% | — | 7.47M | — | 7.65M | HC | — | 2023-02-03 | ↗ |
| 19 | JPMORGAN CHASE & CO.13-2624428 | 7.43M | 8.30% | 6.17M | — | 7.41M | — | HC | Delaware | 2022-01-07 | ↗ |
| 20 | Warford | 7.32M | 8.90% | 7.32M | — | 7.32M | — | IN | United States America | 2021-02-16 | ↗ |
| 21 | The Vanguard Group - 23-1945930 | 7.08M | 8.00% | — | 74.0K | 6.93M | 149.6K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 22 | GOLDMAN SACHS & CO. LLC | 6.11M | 6.40% | — | — | 13.00 | 6.11M | BD, IA, OO | New York | 2023-02-07 | ↗ |
| 23 | THE GOLDMAN SACHS GROUP, INC. | 6.11M | 6.40% | — | — | 13.00 | 6.11M | HC, CO | New York | 2023-02-07 | ↗ |
| 24 | SSGA FUNDS MANAGEMENT, INC. | 5.36M | 5.65% | — | 5.34M | — | 5.36M | IA | — | 2023-02-03 | ↗ |
| 25 | Maverick Capital, Ltd. – 75-2482446 | 4.96M | 9.20% | 4.96M | — | 4.96M | — | IA | — | 2020-02-14 | ↗ |
| 26 | Steven A. Cohen | 4.63M | 4.00% | — | 4.63M | — | 4.63M | IN | Citizenship or place of organization United States | 2022-02-14 | ↗ |
| 27 | Point72 Asset Management, L.P. | 4.61M | 4.00% | — | 4.61M | — | 4.61M | PN | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 28 | Point72 Capital Advisors, Inc. | 4.61M | 4.00% | — | 4.61M | — | 4.61M | CO | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 29 | BRIDGER MANAGEMENT, LLC | 1.52M | 1.80% | — | 1.52M | — | — | IA | Delaware | 2021-02-16 | ↗ |
| 30 | ROBERTO MIGNONE | 1.52M | 1.80% | — | 1.52M | — | — | IN | Delaware | 2021-02-16 | ↗ |
| 31 | Cubist Systematic Strategies, LLC | 18.8K | 4.00% | — | 18.8K | — | 18.8K | OO | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 32 | Point72 Hong Kong Limited | 1.6K | 4.00% | — | 1.6K | — | 1.6K | OO | Citizenship or place of organization Hong Kong | 2022-02-14 | ↗ |
| 33 | Citadel Advisors Holdings LP | 6.00 | 6.40% | — | 6.51M | — | 6.51M | HC, PN | Delaware | 2024-03-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
34
-8 vs prev Q
New positions
7
Closed positions
15
Increased
17
Reduced
3
Put/Call ratio
0.00
Calls held
200.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ECOR1 CAPITAL, LLC | 573.2K +— (+0.0%) | 10.37M +2.2M (+26.2%) | 4.23% -0.474 pp | 0.47% +0.076 pp | USD8.71 +107.7% | 7 qtrs — |
| 2 | REDMILE GROUP, LLC | 441.7K +— (+0.0%) | 7.99M +1.7M (+26.2%) | 3.26% -0.365 pp | 0.59% -0.027 pp | USD8.36 +116.4% | 7 qtrs — |
| 3 | VANGUARD GROUP INC | 225.9K +22.5K (+11.1%) | 4.09M +1.2M (+40.2%) | 1.67% -0.002 pp | 0.00% +0.000 pp | USD9.52 +90.0% | 7 qtrs — |
| 4 | MARSHALL WACE, LLP | 148.6K +32.8K (+28.4%) | 2.69M +1.0M (+62.0%) | 1.10% +0.146 pp | 0.00% +0.001 pp | USD13.28 +36.2% | 5 qtrs — |
| 5 | GLOBEFLEX CAPITAL L P | 77.2K +61.8K (+399.6%) | 1.40M +1.2M (+530.7%) | 0.57% +0.443 pp | 0.21% +0.180 pp | USD17.34 +4.3% | 2 qtrs — |
| 6 | BLACKROCK, INC. | 67.1K -2.7K (-3.9%) | 1.21M +213.3K (+21.3%) | 0.49% -0.078 pp | 0.00% +0.000 pp | USD8.07 +124.2% | 6 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 62.4K +1.9K (+3.1%) | 1.13M +261.6K (+30.2%) | 0.46% -0.036 pp | 0.00% +0.000 pp | USD9.14 +97.9% | 7 qtrs — |
| 8 | MACKENZIE FINANCIAL CORP | 58.7K -5.1K (-8.1%) | 1.05M +132.4K (+14.5%) | 0.43% -0.091 pp | 0.00% +0.000 pp | USD12.00 +50.8% | 3 qtrs — |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 54.0K -2.4K (-4.2%) | 976.0K +169.0K (+20.9%) | 0.40% -0.064 pp | 0.00% +0.000 pp | USD8.34 +116.9% | 7 qtrs — |
| 10 | STALEY CAPITAL ADVISERS INC | 50.0K +— (+0.0%) | 904.5K +188.0K (+26.2%) | 0.37% -0.041 pp | 0.04% +0.008 pp | USD8.07 +124.2% | 7 qtrs — |
| 11 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 32.7K +18.7K (+133.5%) | 591.4K +390.8K (+194.8%) | 0.24% +0.126 pp | 0.01% +0.008 pp | USD13.92 +30.0% | 7 qtrs — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 30.0K +11.1K (+58.6%) | 543.4K +272.1K (+100.3%) | 0.22% +0.066 pp | 0.00% +0.001 pp | USD12.31 +47.0% | 7 qtrs — |
| 13 | STATE STREET CORP | 26.5K +1.2K (+4.8%) | 478.5K +116.7K (+32.2%) | 0.20% -0.012 pp | 0.00% +0.000 pp | USD9.28 +94.9% | 7 qtrs — |
| 14 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | 22.9K +5.8K (+33.6%) | 414.0K +169.0K (+69.0%) | 0.17% +0.028 pp | 0.00% +0.000 pp | USD15.28 +18.4% | 2 qtrs — |
| 15 | QUADRATURE CAPITAL LTD | 20.3K +3.8K (+22.8%) | 367.6K +130.7K (+55.2%) | 0.15% +0.014 pp | 0.00% +0.001 pp | USD15.03 +20.4% | 2 qtrs — |
| 16 | POINT72 ASSET MANAGEMENT, L.P. | 18.3K +18.3K (+100.0%) | 331.0K +331.0K (+100.0%) | 0.13% +0.135 pp | 0.00% +0.000 pp | USD18.09 +0.0% | 1 qtrs NEW |
| 17 | FMR LLC | 17.2K +— (+0.0%) | 310.4K +64.5K (+26.2%) | 0.13% -0.014 pp | 0.00% +0.000 pp | USD8.60 +110.3% | 7 qtrs — |
| 18 | MORGAN STANLEY | 16.0K -19.9K (-55.5%) | 289.3K -225.7K (-43.8%) | 0.12% -0.177 pp | 0.00% +0.000 pp | USD12.48 +45.0% | 7 qtrs — |
| 19 | CITADEL ADVISORS LLC | 15.6K +15.6K (+100.0%) | 281.8K +281.8K (+100.0%) | 0.11% +0.115 pp | 0.00% +0.000 pp | USD18.09 +0.0% | 7 qtrs — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 14.0K +14.0K (+100.0%) | 253.6K +253.6K (+100.0%) | 0.10% +0.103 pp | 0.00% +0.000 pp | USD18.09 +0.0% | 1 qtrs NEW |
| 21 | JANE STREET GROUP, LLC | 14.0K -8.1K (-36.6%) | 253.1K -63.0K (-19.9%) | 0.10% -0.078 pp | 0.00% +0.000 pp | USD14.33 +26.2% | 2 qtrs — |
| 22 | NORTHERN TRUST CORP | 12.3K +1.3K (+11.8%) | 223.2K +65.1K (+41.2%) | 0.09% +0.001 pp | 0.00% +0.000 pp | USD13.82 +30.9% | 7 qtrs — |
| 23 | WALLEYE CAPITAL LLC | 12.2K +12.2K (+100.0%) | 220.1K +220.1K (+100.0%) | 0.09% +0.090 pp | 0.00% +0.001 pp | USD18.09 +0.0% | 1 qtrs NEW |
| 24 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 10.4K +10.4K (+100.0%) | 189.0K +189.0K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.001 pp | USD18.09 +0.0% | 1 qtrs NEW |
| 25 | BANK OF AMERICA CORP /DE/ | 10.4K +4.5K (+77.7%) | 187.9K +104.1K (+124.3%) | 0.08% +0.029 pp | 0.00% +0.000 pp | USD12.62 +43.3% | 7 qtrs — |
| 26 | DIMENSIONAL FUND ADVISORS LP | 10.0K +10.0K (+100.0%) | 181.4K +181.4K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.000 pp | USD18.09 +0.0% | 1 qtrs NEW |
| 27 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.7K +1.4K (+407.9%) | 31.4K +26.5K (+541.1%) | 0.01% +0.010 pp | 0.00% +0.001 pp | USD17.35 +4.3% | 7 qtrs — |
| 28 | SBI SECURITIES CO., LTD. | 1.4K +— (+0.0%) | 25.4K +5.3K (+26.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD13.31 +35.9% | 5 qtrs — |
| 29 | UBS GROUP AG | 1.4K -15.9K (-91.9%) | 25.3K -222.2K (-89.8%) | 0.01% -0.131 pp | 0.00% +0.000 pp | USD10.34 +75.0% | 7 qtrs — |
| 30 | PRIVATE WEALTH ASSET MANAGEMENT, LLC | 900.00 +— (+0.0%) | 16.3K +3.4K (+26.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD14.33 +26.2% | 2 qtrs — |
| 31 | ROYAL BANK OF CANADA | 850.00 -359.0 (-29.7%) | 15.0K -2.0K (-11.8%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD7.10 +154.8% | 7 qtrs — |
| 32 | JONES FINANCIAL COMPANIES LLLP | 703.00 +— (+0.0%) | 12.7K +3.1K (+31.7%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD8.07 +124.2% | 5 qtrs — |
| 33 | WELLS FARGO & COMPANY/MN | 251.00 +— (+0.0%) | 4.5K +944.0 (+26.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.18 +121.1% | 7 qtrs — |
| 34 | JPMORGAN CHASE & CO | 216.00 +— (+0.0%) | 3.9K +812.0 (+26.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.36 +116.4% | 7 qtrs — |
| 35 | BANQUE TRANSATLANTIQUE SA | 176.00 +— (+0.0%) | 3.2K +664.0 (+26.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD13.31 +35.9% | 5 qtrs — |
| 36 | RHUMBLINE ADVISERS | 175.00 +— (+0.0%) | 3.2K +658.0 (+26.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.35 +116.6% | 7 qtrs — |
| 37 | RAIFFEISEN BANK INTERNATIONAL AG | 200.00 +— (+0.0%) | 3.0K +141.0 (+4.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD14.33 +26.2% | 2 qtrs — |
| 38 | FEDERATED HERMES, INC. | 130.00 +130.0 (+100.0%) | 2.4K +2.4K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD18.08 +0.1% | 1 qtrs NEW |
| 39 | BNP PARIBAS ARBITRAGE, SNC | 46.00 -4.0 (-8.0%) | 832.00 +116.0 (+16.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD8.74 +107.0% | 7 qtrs — |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 10.00 +— (+0.0%) | 180.00 +42.0 (+30.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.10 +123.3% | 6 qtrs — |
| 41 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 8.00 +— (+0.0%) | 145.00 +30.0 (+26.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.25 +26.9% | 2 qtrs — |
| 42 | — | 24.00 +— (+0.0%) | 112.00 -210.0 (-65.2%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD14.29 +26.6% | 2 qtrs — |
| 43 | GROUP ONE TRADING, L.P. | — -148.0 (-100.0%) | — -2.1K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 44 | GSA CAPITAL PARTNERS LLP | — -26.2K (-100.0%) | — -376.0K (-100.0%) | 0.00% -0.215 pp | 0.00% -0.031 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 168.1K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 598.0K | 0.05% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 9.7K | 0.17% |
| 4 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.5K | 0.03% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 716.68 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.66M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.6K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.0K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 799.08 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 88.10 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.33
Bearish
Ratio by volume
1.58
Bullish
Buys
1
Sells
3
Shares acquired
507.4K
Shares disposed
321.1K
Cash buys
1.00
Cash sales
3.00
Net activity
+186,306
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 5,241 | 9.13 | 47.8K | 137,837 | D | ↗ |
| 2026-05-18 | Grant-Huerta Yanina | Officer | S-Sale | D | Common Stock | 2,414 | 9.13 | 22.0K | 49,636 | D | ↗ |
| 2026-05-07 | Panacea Innovation Ltd | 10% Owner | S-Sale | D | Common Stock | 313,446 | 10.10 | 3.17M | 1,011,000 | I | ↗ |
| 2026-05-07 | EcoR1 Capital, LLC | 10% Owner | P-Purchase | A | Common Stock | 507,407 | 9.35 | 4.74M | 1,552,000 | I | ↗ |
| 2026-03-17 | Panacea Innovation Ltd | 10% Owner | M-Exempt | A | Common Stock | 259,163 | 0.00 | 25.92 | 307,899 | I | ↗ |
| 2026-03-09 | Nguyen AnhCo | Director / Officer | A-Award | A | Common Stock | 81,100 | 0.00 | — | 143,078 | D | ↗ |
| 2026-03-09 | Grant-Huerta Yanina | Officer | A-Award | A | Common Stock | 20,300 | 0.00 | — | 52,050 | D | ↗ |
| 2026-03-02 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 198 | 5.08 | 1.0K | 64,776 | D | ↗ |
| 2026-03-02 | Grant-Huerta Yanina | Officer | S-Sale | D | Common Stock | 1,603 | 5.08 | 8.1K | 32,227 | D | ↗ |
| 2026-01-12 | Panacea Innovation Ltd | 10% Owner | S-Sale | D | Common Stock | 80,554 | 6.07 | 489.0K | 1,324,446 | I | ↗ |
| 2025-11-28 | Panacea Innovation Ltd | 10% Owner | M-Exempt | D | Warrants | 48,737 | 0.00 | 4.87 | 259,163 | I | ↗ |
| 2025-11-17 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 2,859 | 13.19 | 37.7K | 65,030 | D | ↗ |
| 2025-11-17 | Grant-Huerta Yanina | Officer | S-Sale | D | Common Stock | 1,645 | 13.19 | 21.7K | 33,613 | D | ↗ |
| 2025-08-18 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 57 | 11.61 | 661.94 | 70,790 | D | ↗ |
| 2025-08-18 | Grant-Huerta Yanina | Officer | S-Sale | D | Common Stock | 55 | 11.61 | 638.50 | 37,012 | D | ↗ |
| 2025-08-15 | Panacea Innovation Ltd | 10% Owner | P-Purchase | A | Common Stock | 55,000 | 12.19 | 670.4K | 1,405,000 | I | ↗ |
| 2025-07-17 | Panacea Innovation Ltd | 10% Owner | P-Purchase | A | Common Stock | 19,335 | 9.64 | 186.4K | 1,350,000 | I | ↗ |
| 2025-06-10 | Touchon Pascal | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 77,955 | D | ↗ |
| 2025-06-10 | Roncarolo Maria Grazia | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 17,368 | D | ↗ |
| 2025-06-10 | MALLIK AMEET | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 16,928 | D | ↗ |
| 2025-06-10 | HEIDEN WILLIAM K | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 22,188 | D | ↗ |
| 2025-06-10 | Gallagher Carol Giltner | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 33,012 | D | ↗ |
| 2025-06-10 | Fust Matthew K | Director | A-Award | A | Common Stock | 7,828 | 0.00 | — | 18,188 | D | ↗ |
| 2025-05-16 | Subramanian Nachiappan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-16 | Redmile Group, LLC | Director | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 441,701 | I | ↗ |
| 2025-05-16 | Panacea Innovation Ltd | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 1,330,665 | I | ↗ |
| 2025-05-16 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 3,276 | 6.76 | 22.2K | 70,847 | D | ↗ |
| 2025-05-16 | Grant-Huerta Yanina | Officer | S-Sale | D | Common Stock | 2,218 | 6.76 | 15.0K | 37,067 | D | ↗ |
| 2025-05-16 | Adiumentum Capital Fund I LP | Director / 10% Owner | A-Award | A | Warrants (right to buy) | 227,000 | 0.00 | 22.70 | 377,193 | D | ↗ |
| 2025-03-31 | Hyllengren Eric J | Other | D-Return | D | Employee Stock Option (Right to Buy) | 1,900 | 996.25 | 1.89M | 0 | D | ↗ |
| 2025-03-31 | Grant-Huerta Yanina | Officer | — | — | Common Stock | 0 | 0.00 | — | 39,285 | D | ↗ |
| 2025-03-03 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 3,331 | 7.00 | 23.3K | 74,123 | D | ↗ |
| 2025-03-03 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 1,211 | 7.00 | 8.5K | 56,231 | D | ↗ |
| 2025-03-03 | Henrich Jill | Officer | S-Sale | D | Common Stock | 1,059 | 7.00 | 7.4K | 18,679 | D | ↗ |
| 2025-01-27 | Hyllengren Eric J | Officer | A-Award | A | Common Stock | 34,050 | 0.00 | — | 57,442 | D | ↗ |
| 2024-11-18 | Nguyen AnhCo | Director / Officer | S-Sale | D | Common Stock | 1,664 | 11.20 | 18.6K | 77,454 | D | ↗ |
| 2024-11-18 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 1,364 | 11.20 | 15.3K | 23,392 | D | ↗ |
| 2024-11-18 | Henrich Jill | Officer | S-Sale | D | Common Stock | 1,000 | 11.20 | 11.2K | 19,378 | D | ↗ |
| 2024-09-09 | Nguyen AnhCo | Director / Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 79,118 | — | ↗ |
| 2024-09-03 | Adiumentum Capital Fund I LP | Director / 10% Owner | — | D | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,133,823 | — | ↗ |
| 2024-08-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 2,762 | 6.63 | 18.3K | 70,403 | — | ↗ |
| 2024-08-16 | Nguyen AnhCo | Officer | S-Sale | D | Common Stock | 56 | 6.63 | 371.34 | 34,118 | — | ↗ |
| 2024-08-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 89 | 6.63 | 590.16 | 26,827 | — | ↗ |
| 2024-08-16 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 29 | 6.63 | 192.30 | 24,756 | — | ↗ |
| 2024-08-16 | Henrich Jill | Officer | S-Sale | D | Common Stock | 831 | 6.63 | 5.5K | 20,510 | — | ↗ |
| 2024-08-12 | Touchon Pascal | Director / Officer | D-Return | D | Employee Stock Option (Right to Buy) | 9,000 | 510.75 | 4.60M | 0 | — | ↗ |
| 2024-07-31 | Grant-Huerta Yanina | Officer | — | — | Employee Stock Option (Right to Buy) | 275 | 11.00 | 3.0K | 0 | D | ↗ |
| 2024-05-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 81,506 | 0.62 | 50.3K | 1,829,146 | — | ↗ |
| 2024-05-16 | Nguyen AnhCo | Officer | S-Sale | D | Common Stock | 42,899 | 0.62 | 26.5K | 898,498 | — | ↗ |
| 2024-05-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 32,401 | 0.62 | 20.0K | 695,120 | — | ↗ |
| 2024-05-16 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 28,648 | 0.62 | 17.7K | 645,671 | — | ↗ |
| 2024-05-16 | Henrich Jill | Officer | S-Sale | D | Common Stock | 25,750 | 0.62 | 15.9K | 529,251 | — | ↗ |
| 2024-04-06 | Grant-Huerta Yanina | Officer | — | — | Employee Stock Option (Right to Buy) | 800 | 198.00 | 158.4K | 0 | D | ↗ |
| 2024-03-31 | Roncarolo Maria Grazia | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 238,500 | — | ↗ |
| 2024-03-31 | MALLIK AMEET | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 227,500 | — | ↗ |
| 2024-03-31 | HEIDEN WILLIAM K | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 359,000 | — | ↗ |
| 2024-03-31 | Gallagher Carol Giltner | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 629,608 | — | ↗ |
| 2024-03-31 | Fust Matthew K | Director | A-Award | A | Common Stock | 150,000 | 0.00 | — | 259,000 | — | ↗ |
| 2024-03-04 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 24,844 | 0.72 | 17.9K | 1,910,652 | — | ↗ |
| 2024-03-04 | Nguyen AnhCo | Officer | S-Sale | D | Common Stock | 10,746 | 0.72 | 7.7K | 941,397 | — | ↗ |
| 2024-03-04 | Murugan Amar | Officer | S-Sale | D | Common Stock | 10,044 | 0.72 | 7.2K | 727,521 | — | ↗ |
| 2024-03-04 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 1,462 | 0.72 | 1.1K | 679,536 | — | ↗ |
| 2024-03-04 | Henrich Jill | Officer | S-Sale | D | Common Stock | 3,879 | 0.72 | 2.8K | 555,001 | — | ↗ |
| 2024-01-08 | Touchon Pascal | Director / Officer | A-Award | A | Common Stock | 1,280,000 | 0.00 | — | 1,935,496 | — | ↗ |
| 2024-01-08 | Nguyen AnhCo | Officer | A-Award | A | Common Stock | 675,000 | 0.00 | — | 952,143 | — | ↗ |
| 2024-01-08 | Murugan Amar | Officer | A-Award | A | Common Stock | 475,000 | 0.00 | — | 737,565 | — | ↗ |
| 2024-01-08 | Hyllengren Eric J | Officer | A-Award | A | Common Stock | 475,000 | 0.00 | — | 680,998 | — | ↗ |
| 2024-01-08 | Henrich Jill | Officer | A-Award | A | Common Stock | 450,000 | 0.00 | — | 558,880 | — | ↗ |
| 2023-11-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 20,409 | 0.39 | 7.9K | 655,496 | — | ↗ |
| 2023-11-16 | Nguyen AnhCo | Officer | S-Sale | D | Common Stock | 8,856 | 0.39 | 3.4K | 277,143 | — | ↗ |
| 2023-11-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 8,307 | 0.39 | 3.2K | 257,084 | — | ↗ |
| 2023-11-16 | Joshi Manher | Officer | S-Sale | D | Common Stock | 12,287 | 0.39 | 4.8K | 171,284 | — | ↗ |
| 2023-11-16 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 11,958 | 0.39 | 4.7K | 205,998 | — | ↗ |
| 2023-11-16 | Henrich Jill | Officer | S-Sale | D | Common Stock | 3,267 | 0.39 | 1.3K | 104,424 | — | ↗ |
| 2023-11-14 | Gallagher Carol Giltner | Director | P-Purchase | A | Common Stock | 90,980 | 0.31 | 28.2K | 459,418 | — | ↗ |
| 2023-11-13 | Gallagher Carol Giltner | Director | P-Purchase | A | Common Stock | 179,020 | 0.22 | 40.0K | 368,438 | — | ↗ |
| 2023-11-10 | HEIDEN WILLIAM K | Director | P-Purchase | A | Common Stock | 100,000 | 0.25 | 25.3K | 209,000 | — | ↗ |
| 2023-11-10 | DOBMEIER ERIC | Director | P-Purchase | A | Common Stock | 446,825 | 0.23 | 101.3K | 563,325 | — | ↗ |
| 2023-08-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 9,334 | 1.65 | 15.4K | 675,905 | — | ↗ |
| 2023-08-16 | Nguyen AnhCo | Officer | S-Sale | D | Common Stock | 5,849 | 1.65 | 9.7K | 295,276 | — | ↗ |
| 2023-08-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 3,622 | 1.65 | 6.0K | 265,391 | — | ↗ |
| 2023-08-16 | Joshi Manher | Officer | S-Sale | D | Common Stock | 3,202 | 1.65 | 5.3K | 187,344 | — | ↗ |
| 2023-08-16 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 1,778 | 1.65 | 2.9K | 217,956 | — | ↗ |
| 2023-08-16 | Henrich Jill | Officer | S-Sale | D | Common Stock | 2,788 | 1.65 | 4.6K | 108,249 | — | ↗ |
| 2023-06-27 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 14,291 | 1.66 | 23.7K | 706,671 | — | ↗ |
| 2023-06-01 | Nguyen AnhCo | Officer | — | D | Employee Stock Option (Right to Buy) | 87,125 | 13.24 | 1.15M | 0 | — | ↗ |
| 2023-06-01 | Joshi Manher | Officer | — | D | Employee Stock Option (Right to Buy) | 68,991 | 10.21 | 704.4K | 0 | — | ↗ |
| 2023-06-01 | Henrich Jill | Officer | — | D | Employee Stock Option (Right to Buy) | 86,564 | 3.91 | 338.5K | 0 | — | ↗ |
| 2023-05-31 | SEIDENBERG BETH C | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-31 | Roncarolo Maria Grazia | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-31 | MALLIK AMEET | Director | A-Award | A | Common Stock | 57,000 | 0.00 | — | 77,500 | — | ↗ |
| 2023-05-31 | HEIDEN WILLIAM K | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-31 | Gallagher Carol Giltner | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-31 | Fust Matthew K | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-31 | DOBMEIER ERIC | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 79,500 | 1.53 | 121.6K | 79,500 | — | ↗ |
| 2023-05-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 29,766 | 2.04 | 60.6K | 720,962 | — | ↗ |
| 2023-05-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 7,404 | 2.04 | 15.1K | 271,930 | — | ↗ |
| 2023-05-16 | Hyllengren Eric J | Officer | S-Sale | D | Common Stock | 1,719 | 2.04 | 3.5K | 226,142 | — | ↗ |
| 2023-05-16 | Banard Charlene A. | Officer | S-Sale | D | Common Stock | 19,040 | 2.04 | 38.8K | 276,010 | — | ↗ |
| 2023-04-01 | Hyllengren Eric J | Officer | — | D | Common Stock | 0 | 0.00 | — | 234,060 | — | ↗ |
| 2023-03-02 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 15,679 | 3.63 | 56.9K | 750,728 | — | ↗ |
| 2023-03-02 | Murugan Amar | Officer | S-Sale | D | Common Stock | 4,221 | 3.63 | 15.3K | 279,334 | — | ↗ |
| 2023-03-02 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 6,871 | 3.63 | 24.9K | 181,978 | — | ↗ |
| 2023-03-02 | Dupont Jakob | Officer | S-Sale | D | Common Stock | 5,074 | 3.63 | 18.4K | 290,794 | — | ↗ |
| 2023-03-01 | Touchon Pascal | Director / Officer | A-Award | A | Common Stock | 324,711 | 0.00 | — | 766,407 | — | ↗ |
| 2023-03-01 | Murugan Amar | Officer | A-Award | A | Common Stock | 155,375 | 0.00 | — | 283,555 | — | ↗ |
| 2023-03-01 | Dupont Jakob | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 317,987 | 3.91 | 1.24M | 317,987 | — | ↗ |
| 2023-03-01 | Banard Charlene A. | Officer | A-Award | A | Common Stock | 139,700 | 0.00 | — | 295,050 | — | ↗ |
| 2023-02-07 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 2,485 | 5.46 | 13.6K | 188,849 | — | ↗ |
| 2023-02-06 | Joshi Manher | Officer | — | D | Employee Stock Option (Right to Buy) | 30,350 | 38.47 | 1.17M | 0 | — | ↗ |
| 2023-02-06 | Hyllengren Eric J | Officer | — | D | Employee Stock Option (Right to Buy) | 11,500 | 38.47 | 442.4K | 0 | — | ↗ |
| 2022-12-14 | Banard Charlene A. | Officer | — | D | Employee Stock Option (Right to Buy) | 292,023 | 7.29 | 2.13M | — | — | ↗ |
| 2022-11-16 | Touchon Pascal | Director | S-Sale | D | Common Stock | 15,591 | 4.49 | 70.0K | 441,696 | — | ↗ |
| 2022-11-16 | Murugan Amar | Director | S-Sale | D | Common Stock | 3,612 | 4.49 | 16.2K | 127,586 | — | ↗ |
| 2022-11-16 | Koppikar Utpal | Director / Officer | S-Sale | D | Common Stock | 5,172 | 4.49 | 23.2K | 192,417 | — | ↗ |
| 2022-11-16 | Dupont Jakob | Director | S-Sale | D | Common Stock | 3,218 | 4.49 | 14.4K | 155,664 | — | ↗ |
| 2022-08-20 | Hyllengren Eric J | Officer | — | D | Employee Stock Option (Right to Buy) | 47,500 | 39.85 | 1.89M | 0 | — | ↗ |
| 2022-08-16 | Touchon Pascal | Director | S-Sale | D | Common Stock | 14,806 | 5.04 | 74.5K | 457,287 | — | ↗ |
| 2022-08-16 | Murugan Amar | Director | S-Sale | D | Common Stock | 1,196 | 5.03 | 6.0K | 133,432 | — | ↗ |
| 2022-08-16 | Koppikar Utpal | Director / Officer | S-Sale | D | Common Stock | 5,940 | 5.04 | 29.9K | 197,589 | — | ↗ |
| 2022-08-16 | Dupont Jakob | Director | S-Sale | D | Common Stock | 4,124 | 5.03 | 20.8K | 158,882 | — | ↗ |
| 2022-06-27 | Touchon Pascal | Officer | S-Sale | D | Common Stock | 14,220 | 7.20 | 102.4K | 472,093 | — | ↗ |
| 2022-06-23 | SEIDENBERG BETH C | Director | A-Award | A | Common Stock | 20,500 | 0.00 | — | 58,689 | — | ↗ |
| 2022-06-23 | Roncarolo Maria Grazia | Director | A-Award | A | Common Stock | 20,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-06-23 | Renaud Ronald C JR | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-06-23 | MALLIK AMEET | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-06-23 | HEIDEN WILLIAM K | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-06-23 | Gallagher Carol Giltner | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 7.35 | 231.5K | 31,500 | — | ↗ |
| 2022-06-23 | Fust Matthew K | Director | A-Award | A | Common Stock | 20,500 | 0.00 | — | 52,000 | — | ↗ |
| 2022-06-23 | DOBMEIER ERIC | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 0.00 | — | 31,500 | — | ↗ |
| 2022-06-23 | Baynes Roy D. | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 31,500 | 7.35 | 231.5K | 31,500 | — | ↗ |
| 2022-06-08 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 5,853 | 5.63 | 33.0K | 203,529 | — | ↗ |
| 2022-05-17 | Touchon Pascal | Director | S-Sale | D | Common Stock | 13,913 | 5.32 | 74.0K | 486,313 | — | ↗ |
| 2022-05-17 | Murugan Amar | Officer | S-Sale | D | Common Stock | 2,317 | 5.32 | 12.3K | 134,641 | — | ↗ |
| 2022-05-17 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 4,616 | 5.32 | 24.5K | 208,558 | — | ↗ |
| 2022-05-17 | Dupont Jakob | Director | S-Sale | D | Common Stock | 3,873 | 5.32 | 20.6K | 163,006 | — | ↗ |
| 2022-03-01 | Yarema Kristin | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 85,592 | 0.00 | — | 85,592 | — | ↗ |
| 2022-03-01 | Touchon Pascal | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 339,419 | 10.21 | 3.47M | 339,419 | — | ↗ |
| 2022-03-01 | Murugan Amar | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 97,398 | 10.21 | 994.4K | 97,398 | — | ↗ |
| 2022-03-01 | Koppikar Utpal | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 115,107 | 0.00 | — | 115,107 | — | ↗ |
| 2022-03-01 | Dupont Jakob | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 147,573 | 10.21 | 1.51M | 147,573 | — | ↗ |
| 2022-02-10 | Dupont Jakob | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,000 | 9.58 | 47.9K | 257,500 | — | ↗ |
| 2022-02-07 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 2,496 | 14.46 | 36.1K | 155,702 | — | ↗ |
| 2022-02-06 | Joshi Manher | Officer | — | D | Employee Stock Option (Right to Buy) | 35,000 | 35.80 | 1.25M | 0 | — | ↗ |
| 2022-01-03 | Dupont Jakob | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,000 | 9.58 | 47.9K | 262,500 | — | ↗ |
| 2021-12-01 | Dupont Jakob | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,000 | 9.58 | 47.9K | 267,500 | — | ↗ |
| 2021-11-16 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 8,402 | 17.12 | 143.8K | 328,489 | — | ↗ |
| 2021-11-16 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,332 | 17.12 | 57.0K | 113,097 | — | ↗ |
| 2021-11-16 | Murugan Amar | Officer | S-Sale | D | Common Stock | 2,124 | 17.12 | 36.4K | 87,540 | — | ↗ |
| 2021-11-16 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 3,655 | 17.12 | 62.6K | 157,714 | — | ↗ |
| 2021-11-16 | Dupont Jakob | Officer | S-Sale | D | Common Stock | 2,199 | 17.12 | 37.6K | 90,594 | — | ↗ |
| 2021-11-15 | Newell Joe | Officer | M-Exempt | A | Common Stock | 3,500 | 12.15 | 42.5K | 123,429 | — | ↗ |
| 2021-11-04 | Fust Matthew K | Director | S-Sale | D | Common Stock | 13,354 | 19.50 | 260.4K | 31,500 | — | ↗ |
| 2021-11-02 | Dupont Jakob | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,000 | 9.58 | 47.9K | 272,500 | — | ↗ |
| 2021-09-22 | Newell Joe | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 8,375 | 12.15 | 101.8K | 34,875 | — | ↗ |
| 2021-09-15 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,116 | 15.61 | 48.6K | 119,929 | — | ↗ |
| 2021-08-30 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,500 | 15.00 | 52.5K | 123,045 | — | ↗ |
| 2021-08-17 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 8,223 | 12.53 | 103.1K | 336,891 | — | ↗ |
| 2021-08-17 | Newell Joe | Officer | S-Sale | D | Common Stock | 2,426 | 12.53 | 30.4K | 126,545 | — | ↗ |
| 2021-08-17 | Murugan Amar | Officer | S-Sale | D | Common Stock | 2,080 | 12.53 | 26.1K | 89,664 | — | ↗ |
| 2021-08-17 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 3,579 | 12.53 | 44.9K | 161,369 | — | ↗ |
| 2021-08-17 | Dupont Jakob | Officer | S-Sale | D | Common Stock | 2,152 | 12.53 | 27.0K | 92,793 | — | ↗ |
| 2021-08-09 | MALLIK AMEET | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 55,000 | 12.49 | 687.0K | 55,000 | — | ↗ |
| 2021-06-25 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 14,194 | 16.32 | 231.7K | 345,114 | — | ↗ |
| 2021-06-14 | Yarema Kristin | Officer | P-Purchase | A | Common Stock | 28,833 | 14.58 | 420.4K | 125,882 | — | ↗ |
| 2021-06-11 | Yarema Kristin | Officer | P-Purchase | A | Common Stock | 2,021 | 14.50 | 29.3K | 93,549 | — | ↗ |
| 2021-06-08 | SEIDENBERG BETH C | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 17,500 | 13.80 | 241.5K | 17,500 | — | ↗ |
| 2021-06-08 | Roncarolo Maria Grazia | Director | A-Award | A | Common Stock | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2021-06-08 | Renaud Ronald C JR | Director | A-Award | A | Common Stock | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2021-06-08 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 5,820 | 14.06 | 81.8K | 164,948 | — | ↗ |
| 2021-06-08 | HEIDEN WILLIAM K | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 17,500 | 13.80 | 241.5K | 17,500 | — | ↗ |
| 2021-06-08 | Gallagher Carol Giltner | Director | A-Award | A | Common Stock | 11,000 | 0.00 | — | 111,818 | — | ↗ |
| 2021-06-08 | Fust Matthew K | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 17,500 | 13.80 | 241.5K | 17,500 | — | ↗ |
| 2021-06-08 | DOBMEIER ERIC | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 17,500 | 13.80 | 241.5K | 17,500 | — | ↗ |
| 2021-06-08 | Baynes Roy D. | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 17,500 | 13.80 | 241.5K | 17,500 | — | ↗ |
| 2021-05-18 | Yarema Kristin | Officer | S-Sale | D | Common Stock | 761 | 14.55 | 11.1K | 91,528 | — | ↗ |
| 2021-05-18 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 8,313 | 14.55 | 121.0K | 359,308 | — | ↗ |
| 2021-05-18 | Newell Joe | Officer | S-Sale | D | Common Stock | 2,453 | 14.55 | 35.7K | 128,971 | — | ↗ |
| 2021-05-18 | Murugan Amar | Officer | S-Sale | D | Common Stock | 5,681 | 14.55 | 82.7K | 91,744 | — | ↗ |
| 2021-05-18 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 3,616 | 14.55 | 52.6K | 168,966 | — | ↗ |
| 2021-05-18 | Dupont Jakob | Officer | S-Sale | D | Common Stock | 5,184 | 14.55 | 75.4K | 94,945 | — | ↗ |
| 2021-05-17 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,500 | 15.00 | 52.5K | 131,424 | — | ↗ |
| 2021-04-05 | Newell Joe | Officer | S-Sale | D | Common Stock | 655 | 14.74 | 9.7K | 134,924 | — | ↗ |
| 2021-03-26 | Newell Joe | Officer | S-Sale | D | Common Stock | 2,640 | 14.58 | 38.5K | 135,579 | — | ↗ |
| 2021-03-26 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 1,761 | 14.58 | 25.7K | 172,582 | — | ↗ |
| 2021-03-15 | Newell Joe | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 2,791 | 12.15 | 33.9K | 43,250 | — | ↗ |
| 2021-03-02 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 4,887 | 16.74 | 81.8K | 367,621 | — | ↗ |
| 2021-03-02 | Newell Joe | Officer | S-Sale | D | Common Stock | 1,665 | 16.74 | 27.9K | 141,719 | — | ↗ |
| 2021-03-02 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 1,461 | 16.74 | 24.5K | 174,343 | — | ↗ |
| 2021-03-01 | Yarema Kristin | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 52,862 | 17.11 | 904.2K | 52,862 | — | ↗ |
| 2021-03-01 | Touchon Pascal | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 176,886 | 17.11 | 3.03M | 176,886 | — | ↗ |
| 2021-03-01 | Newell Joe | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 56,929 | 17.11 | 973.8K | 56,929 | — | ↗ |
| 2021-03-01 | Murugan Amar | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 63,028 | 17.11 | 1.08M | 63,028 | — | ↗ |
| 2021-03-01 | Koppikar Utpal | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 68,314 | 17.11 | 1.17M | 68,314 | — | ↗ |
| 2021-03-01 | Dupont Jakob | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 81,327 | 17.11 | 1.39M | 81,327 | — | ↗ |
| 2021-02-08 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,886 | 20.39 | 79.2K | 105,669 | — | ↗ |
| 2021-02-08 | Koppikar Utpal | Officer | S-Sale | D | Common Stock | 1,759 | 20.39 | 35.9K | 130,546 | — | ↗ |
| 2021-01-15 | Newell Joe | Officer | M-Exempt | A | Common Stock | 3,500 | 12.15 | 42.5K | 116,555 | — | ↗ |
| 2020-12-16 | Newell Joe | Officer | S-Sale | D | Common Stock | 3,500 | 23.08 | 80.8K | 113,055 | — | ↗ |
| 2020-11-17 | Touchon Pascal | Director / Officer | S-Sale | D | Common Stock | 4,716 | 19.77 | 93.3K | 255,321 | — | ↗ |
Executive team
Top executives
EBIT / Employee
238.6K
Shares Outstanding
9.01M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Pascal Touchon, D.V.M. Former President and Chief Executive Officer | 503.6K | — | 716.8K | — | — | 501.9K | 1.72M | 41.62% | ↗ |
| 2 | 2024 | AnhCo Nguyen, Ph.D. President and Chief Executive Officer | 585.8K | 51.5K | 781.7K | — | 145.8K | 8.9K | 1.57M | 49.67% | ↗ |
| 3 | 2024 | Eric Hyllengren Former EVP, Chief Financial Officer and Chief Operating Officer | 489.8K | 42.4K | 266.0K | — | 117.0K | 11.0K | 926.1K | 28.72% | ↗ |
| 4 | 2024 | Amar Murugan Former EVP, Chief Legal Officer | 447.7K | 49.2K | 266.0K | — | — | 115.5K | 878.4K | 30.28% | ↗ |
| 5 | 2024 | Jill Henrich Former EVP, Chief Regulatory Officer | 503.8K | 45.0K | 252.0K | — | — | 11.7K | 812.5K | 31.01% | ↗ |
| 6 | 2023 | Pascal Touchon, D.V.M. President and Chief Executive Officer | 723.5K | 75.0K | 1.27M | 2.06M | 235.1K | 11.1K | 4.38M | 76.12% | ↗ |
| 7 | 2023 | Pascal Touchon, D.V.M. Former President and Chief Executive Officer | 723.5K | 75.0K | 1.27M | 2.06M | 235.1K | 11.1K | 4.38M | 76.12% | ↗ |
| 8 | 2023 | Amar Murugan Former EVP, Chief Legal Officer | 515.0K | 50.0K | 607.5K | 986.1K | 141.9K | 11.6K | 2.31M | 68.92% | ↗ |
| 9 | 2023 | Amar Murugan EVP, Chief Legal Officer | 515.0K | 50.0K | 607.5K | 986.1K | 141.9K | 11.6K | 2.31M | 68.92% | ↗ |
| 10 | 2023 | AnhCo Nguyen, Ph.D. President and Chief Executive Officer | 539.6K | — | 602.8K | 978.5K | 148.6K | 8.2K | 2.28M | 69.43% | ↗ |
| 11 | 2023 | AnhCo Nguyen, Ph.D. EVP, Chief Scientific and Technical Officer | 539.6K | — | 602.8K | 978.5K | 148.6K | 8.2K | 2.28M | 69.43% | ↗ |
| 12 | 2022 | Pascal Touchon, D.V.M. President & Chief Executive Officer | 717.9K | — | 1.84M | 2.24M | 349.6K | 10.3K | 5.16M | 79.10% | ↗ |
| 13 | 2022 | Pascal Touchon, D.V.M. President and Chief Executive Officer | 717.9K | — | 1.84M | 2.24M | 349.6K | 10.3K | 5.16M | 79.10% | ↗ |
| 14 | 2022 | Charlene Banard EVP, Chief Technical Officer | 297.7K | 50.0K | 1.13M | 1.42M | 102.6K | 203.7K | 3.20M | 79.58% | ↗ |
| 15 | 2022 | Jakob Dupont, M.D. EVP, Global Head of Research and Development | 542.5K | — | 801.5K | 972.5K | 197.6K | 10.5K | 2.52M | 70.27% | ↗ |
| 16 | 2022 | Utpal Koppikar EVP, Chief Financial Officer | 500.5K | — | 625.2K | 758.5K | 185.6K | 13.8K | 2.08M | 66.41% | ↗ |
| 17 | 2022 | Amar Murugan EVP, Chief Legal Officer | 457.3K | — | 529.0K | 641.8K | 150.4K | 10.8K | 1.79M | 65.43% | ↗ |
| 18 | 2021 | Pascal Touchon, D.V.M. President & Chief Executive Officer | 680.6K | — | 2.00M | 2.00M | 418.4K | 9.3K | 5.12M | 78.34% | ↗ |
| 19 | 2021 | Jakob Dupont, M.D. EVP, Global Head of Research and Development Utpal Koppikar Chief Financial Officer | 519.2K | 130.0K | 921.6K | 921.6K | 228.0K | 7.9K | 2.73M | 67.56% | ↗ |
| 20 | 2021 | Jakob Dupont, M.D. EVP, Global Head of Research and Development | 519.2K | 130.0K | 921.6K | 921.6K | 228.0K | 7.9K | 2.73M | 67.56% | ↗ |
| 21 | 2021 | Utpal Koppikar EVP, Chief Financial Officer | 475.1K | — | 774.1K | 774.2K | 188.2K | 13.0K | 2.22M | 69.60% | ↗ |
| 22 | 2021 | Amar Murugan SVP, General Counsel | 431.0K | — | 714.2K | 714.3K | 170.8K | 10.0K | 2.04M | 70.02% | ↗ |
| 23 | 2021 | Amar Murugan EVP, Chief Legal Officer | 431.0K | — | 714.2K | 714.3K | 170.8K | 10.0K | 2.04M | 70.02% | ↗ |
| 24 | 2021 | Kristin Yarema, Ph.D. SVP, Chief Commercial Officer | 436.2K | 75.0K | 599.0K | 599.0K | 170.2K | 10.0K | 1.89M | 63.41% | ↗ |
| 25 | 2020 | Pascal Touchon, D.V.M. President & Chief Executive Officer | 654.9K | — | 2.24M | 1.96M | 422.5K | 13.7K | 5.29M | 79.36% | ↗ |
| 26 | 2020 | Jakob Dupont, M.D. EVP, Global Head of Research and Development Utpal Koppikar Chief Financial Officer | 319.2K | 130.0K | 443.1K | 1.76M | 143.3K | 3.3K | 2.80M | 78.69% | ↗ |
| 27 | 2020 | Jakob Dupont, M.D. EVP, Global Head of Research and Development | 319.2K | 130.0K | 443.1K | 1.76M | 143.3K | 3.3K | 2.80M | 78.69% | ↗ |
| 28 | 2020 | Kristin Yarema, Ph.D. SVP, Chief Commercial Officer | 368.3K | 175.0K | 668.3K | 1.07M | 148.0K | 9.4K | 2.44M | 71.24% | ↗ |
| 29 | 2020 | Joseph Newell EVP, Chief Operations Officer | 466.1K | 203.4K | 1.03M | 566.7K | — | 895.00 | 2.25M | 71.11% | ↗ |
| 30 | 2020 | Utpal Koppikar EVP, Chief Financial Officer | 460.9K | — | 885.4K | 597.1K | 187.0K | 7.5K | 2.14M | 69.34% | ↗ |
| 31 | 2020 | Utpal Koppikar Chief Financial Officer | 460.9K | 187.0K | 885.4K | 597.1K | — | 7.5K | 2.14M | 69.34% | ↗ |
| 32 | 2019 | Isaac Ciechanover M.D. Former President & Chief Executive Officer | 384.0K | — | 5.86M | 879.5K | — | 888.8K | 8.01M | 84.12% | ↗ |
| 33 | 2019 | Pascal Touchon, D.V.M. President & Chief Executive Officer | 319.3K | — | 2.86M | 3.05M | 334.8K | 71.8K | 6.64M | 89.06% | ↗ |
| 34 | 2019 | Dietmar Berger, M.D., Ph.D. Former Global Head of Research & Development | 246.1K | — | 1.53M | 1.33M | — | 137.8K | 3.25M | 88.17% | ↗ |
| 35 | 2019 | Joseph Newell EVP, Chief Operations Officer | 390.0K | 155.2K | 1.24M | 932.4K | — | 895.00 | 2.72M | 79.92% | ↗ |
| 36 | 2019 | Joseph Newell EVP, Chief Technical Operations Officer | 390.0K | 155.2K | 1.24M | 932.4K | — | 895.00 | 2.72M | 79.92% | ↗ |
| 37 | 2019 | Utpal Koppikar Chief Financial Officer | 439.9K | 155.6K | 1.03M | 909.1K | — | 895.00 | 2.54M | 76.52% | ↗ |
| 38 | 2019 | Jakob Dupont, M.D. EVP, Global Head of Research and Development Utpal Koppikar Chief Financial Officer | 439.9K | — | 1.03M | 909.1K | 155.6K | 895.00 | 2.54M | 76.52% | ↗ |
| 39 | 2019 | Mina Kim Former SVP, Corporate Strategy and General Counsel | 364.5K | — | 1.03M | 909.1K | — | 20.5K | 2.33M | 83.47% | ↗ |
| 40 | 2018 | Isaac Ciechanover President & Chief Executive Officer | 607.1K | 440.1K | 2.33M | 2.76M | — | 689.00 | 6.13M | 82.91% | ↗ |
| 41 | 2018 | Isaac Ciechanover M.D. Former President & Chief Executive Officer | 607.1K | 440.1K | 2.33M | 2.76M | — | 689.00 | 6.13M | 82.91% | ↗ |
| 42 | 2018 | Dietmar Berger Global Head of Research & Development | 320.4K | 427.8K | 2.10M | 2.12M | — | 451.00 | 4.97M | 84.94% | ↗ |
| 43 | 2018 | Dietmar Berger, M.D., Ph.D. Former Global Head of Research & Development | 320.4K | 427.8K | 2.10M | 2.12M | — | 451.00 | 4.97M | 84.94% | ↗ |
| 44 | 2018 | Utpal Koppikar Chief Financial Officer | 240.3K | 189.8K | 1.90M | 1.89M | — | 398.00 | 4.22M | 89.80% | ↗ |
| 45 | 2018 | Mina Kim SVP, Corporate Strategy and General Counsel | 266.8K | 101.7K | 1.53M | 1.49M | — | 504.00 | 3.38M | 89.10% | ↗ |
| 46 | 2018 | Mina Kim Former SVP, Corporate Strategy and General Counsel | 266.8K | 101.7K | 1.53M | 1.49M | — | 504.00 | 3.38M | 89.10% | ↗ |
| 47 | 2018 | Joseph Newell EVP, Chief Operations Officer | 365.0K | 155.5K | 895.0K | 1.06M | — | 16.1K | 2.49M | 78.47% | ↗ |
| 48 | 2018 | Joseph Newell EVP, Chief Technical Operations Officer | 365.0K | 155.5K | 895.0K | 1.06M | — | 16.1K | 2.49M | 78.47% | ↗ |
| 49 | 2018 | John McGrath Former Chief Financial Officer | 143.5K | — | 895.0K | 1.06M | — | 212.00 | 2.10M | 93.15% | ↗ |
| 50 | 2017 | Isaac Ciechanover President & Chief Executive Officer | 562.4K | 320.5K | 2.48M | — | — | 689.00 | 3.37M | 73.76% | ↗ |
| 51 | 2017 | Isaac Ciechanover M.D. Former President & Chief Executive Officer | 562.4K | 320.5K | 2.48M | — | — | 689.00 | 3.37M | 73.76% | ↗ |
| 52 | 2017 | Isaac E. Ciechanover, M.D. President and Chief Executive Officer | 562.4K | 320.5K | 2.48M | — | — | 689.00 | 3.37M | 73.76% | ↗ |
| 53 | 2017 | Joseph Newell EVP and Chief Technical Operations Officer | 258.8K | 191.9K | 153.0K | 1.04M | — | 174.0K | 1.82M | 65.60% | ↗ |
| 54 | 2017 | Joseph Newell EVP, Chief Technical Operations Officer | 258.8K | 191.9K | 153.0K | 1.04M | — | 174.0K | 1.82M | 65.60% | ↗ |
| 55 | 2017 | Derrell D. Porter, M.D. SVP and Global Commercial Head | 235.8K | 221.6K | — | 1.05M | — | 689.00 | 1.51M | 69.67% | ↗ |
| 56 | 2017 | John McGrath Former Chief Financial Officer | 336.0K | 127.7K | 745.0K | — | — | 689.00 | 1.24M | 60.11% | ↗ |
| 57 | 2016 | Isaac Ciechanover President & Chief Executive Officer | 546.0K | 327.9K | 9.13M | — | — | 5.9K | 10.01M | 91.22% | ↗ |
| 58 | 2016 | Isaac E. Ciechanover, M.D. President and Chief Executive Officer | 546.0K | 327.9K | 9.13M | — | — | 5.9K | 10.01M | 91.22% | ↗ |
| 59 | 2016 | Christopher Haqq, M.D., Ph.D. EVP, R&D and Chief Scientific Officer | 416.0K | 154.8K | 2.72M | — | — | 3.8K | 3.30M | 82.58% | ↗ |
| 60 | 2016 | Gad Soffer EVP and Chief Strategy Officer | 358.8K | 131.3K | 2.61M | — | — | 2.0K | 3.10M | 84.11% | ↗ |
| 61 | 2016 | John McGrath Former Chief Financial Officer | 355.4K | 132.2K | 676.3K | — | — | 3.5K | 1.17M | 57.94% | ↗ |
| 62 | 2015 | Isaac E. Ciechanover, M.D. President and Chief Executive Officer | 506.3K | 419.6K | 955.7K | 4.66M | — | 5.3K | 6.55M | 85.77% | ↗ |
| 63 | 2015 | Isaac E. Ciechanover, M.D. Chief Executive Officer | 506.3K | 419.6K | 955.7K | 4.66M | — | 5.3K | 6.55M | 85.77% | ↗ |
| 64 | 2015 | Heather Turner Vice President, General Counsel and Secretary | 159.6K | 88.1K | — | 5.14M | — | 40.7K | 5.43M | 94.69% | ↗ |
| 65 | 2015 | Christopher Haqq, M.D., Ph.D. Chief Medical Officer | 381.3K | 198.3K | 311.9K | 1.56M | — | 3.3K | 2.46M | 76.28% | ↗ |
| 66 | 2015 | Christopher Haqq, M.D., Ph.D. EVP, R&D and Chief Scientific Officer | 381.3K | 198.3K | 311.9K | 1.56M | — | 3.3K | 2.46M | 76.28% | ↗ |
| 67 | 2014 | Isaac E. Ciechanover, M.D. Chief Executive Officer | 410.8K | 420.1K | 812.2K | 907.2K | — | 4.9K | 2.56M | 67.29% | ↗ |
| 68 | 2014 | Mitchall G. Clark Chief Regulatory Officer | 231.8K | 90.6K | 991.5K | 87.8K | — | 1.2K | 1.40M | 76.93% | ↗ |
| 69 | 2014 | Christopher Haqq, M.D., Ph.D. Chief Medical Officer | 333.2K | 168.8K | 114.0K | 292.7K | — | 2.0K | 910.6K | 44.66% | ↗ |
| 70 | 2014 | Christopher Haqq Chief Medical Officer | 333.2K | 168.8K | 114.0K | 292.7K | — | 2.0K | 910.6K | 44.66% | ↗ |
| 71 | 2013 | Isaac E. Ciechanover, M.D. Chief Executive Officer | 370.0K | 187.1K | — | — | — | 4.7K | 561.8K | 0.00% | ↗ |
| 72 | 2013 | Christopher Haqq Chief Medical Officer | 310.0K | 93.0K | — | — | — | 100.4K | 503.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anhco Nguyen | President, Chief Executive Officer & Director | 1M | — |
| Alex Chapman | Vice President of Corporate Communications & Investor Relations | — | — |
| Jim Sesic | Senior Vice President of Regulatory Affairs | — | male |
| John Chao | Head of Legal | — | male |
| Yanina Grant-Huerta | Chief Accounting Officer & Principal Accounting Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATRA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
